Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Inotrem’s lead asset, Nangibotide, is currently evaluated in two clinical trials : a phase 2b in septic shock patients, with results expected in Q3 2022, and a phase 2/3 in patients with severe forms of COVID-19.
In parallel, Inotrem has also launched an antibody-based program to develop a new therapeutic modality targeting chronic inflammatory diseases.
Inotrem has a personalized healthcare approach with a mechanism-based biomarker (soluble TREM-1) being developed in collaboration with Roche Diagnostics as a companion diagnostic tool to select the patients more likely to benefit from a treatment by nangibotide.
Inotrem is supported by leading European and US investors.
In parallel, Inotrem has also launched an antibody-based program to develop a new therapeutic modality targeting chronic inflammatory diseases.
Inotrem has a personalized healthcare approach with a mechanism-based biomarker (soluble TREM-1) being developed in collaboration with Roche Diagnostics as a companion diagnostic tool to select the patients more likely to benefit from a treatment by nangibotide.
Inotrem is supported by leading European and US investors.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
France
Year Founded:
2013
Main Therapeutic Focus:
Lead Product in Development:
Nangibotide
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
